Growing pomegranate trees and worried about flatheaded borer infestations? Lanfeng Hemei helps you secure this season.
Pomegranate tree husk disease (macula disease) is a common disease on pomegranate trees, with its occurrence closely related to overcast and rainy weather as well as high humidity. Once the disease develops, it causes leaf spotting and premature defoliation, thereby reducing yield. The control of pomegranate tree husk disease emphasizes early prevention and the selection of targeted fungicides—Lanfeng Hemei 5% Pyraclostrobin + 55% Metiram is registered for use against pomegranate tree husk disease and can be applied by foliar spraying according to the label instructions.
Pomegranate tree rough bark disease typically shows symptoms on leaves first, with lesions spreading from the lower to the upper canopy and increasing in number over time. In the early stage, the symptoms are inconspicuous; by the time the lesions coalesce into larger patches and spraying is initiated, it is often already too late. Therefore, frequent field scouting is essential—apply the first spray as soon as lesions appear on pomegranate trees to suppress the pathogen at its source.
Lanfeng Hemei 5% Pyraclostrobin + 55% Metiram, registration certificate No. PD20183729 (subject to the actual label). Primarily controls pomegranate fruit blotch (marbling disease), and also provides secondary control of apple alternaria blotch (spotted leaf disease). Dilute at 2000–3000× with water and apply as a foliar spray. Spray at the early stage of disease onset, and a repeat application may be made at 7–10-day intervals depending on disease severity. Ensure sufficient water volume and thoroughly wet the affected plant parts.
Prolonged consecutive use of pyraclostrobin and similar fungicides can readily induce pathogen resistance. It is recommended to rotate with fungicides of different mechanisms of action. For specific dosage and water volume, always refer to the product label. Since crop varieties and weather conditions vary by region, do not blindly copy application regimens from other areas.